Anzeige
Mehr »
Sonntag, 26.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PU3T | ISIN: US81642T2096 | Ticker-Symbol: RXK3
Tradegate
24.10.25 | 20:17
1,736 Euro
+1,64 % +0,028
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SELLAS LIFE SCIENCES GROUP INC Chart 1 Jahr
5-Tage-Chart
SELLAS LIFE SCIENCES GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7001,78025.10.
1,6861,72824.10.

Aktuelle News zur SELLAS LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.10.SELLAS to present CDK9 inhibitor data for T-cell leukemia at ESMO7
13.10.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) ...7
10.10.Sellas Life Sciences files to sell 19.69M shares of common stock for holders6
03.10.SELLAS Life Sciences Group, Inc. - 8-K, Current Report6
30.09.SELLAS Life Sciences to host virtual R&D day on AML treatments2
30.09.SELLAS Life Sciences veranstaltet virtuellen F&E-Tag zu AML-Therapien1
SELLAS LIFE SCIENCES Aktie jetzt für 0€ handeln
30.09.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and ...3
11.09.SELLAS Life Sciences Group, Inc. - 8-K, Current Report9
11.09.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds5
12.08.SELLAS Life Sciences Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans5
12.08.SELLAS Life Sciences Group, Inc. - 8-K, Current Report3
12.08.SELLAS Life Sciences Group, Inc. - 10-Q, Quarterly Report8
07.08.SELLAS Life Sciences Gets Positive IDMC Nod To Continue Phase 3 Trial Of AML Treatment4
07.08.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification294- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the...
► Artikel lesen
15.07.Sellas' CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study9
15.07.Sellas Flat on Trial Success7
15.07.SELLAS gains as mid-stage trial for leukemia drug succeeds6
15.07.SELLAS Life Sciences Group, Inc.: SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study205The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30...
► Artikel lesen
07.07.Krebsforschungs-Expertin verstärkt wissenschaftlichen Beirat von SELLAS Life Sciences12
07.07.SELLAS Life Sciences adds cancer research expert to scientific board3
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1